Compare DexCom, Inc. (DXCM) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? DexCom, Inc. trades at $77.18 (market cap $28.06B), while Vanguard Ultra Short Bond ETF trades at $49.7. The key difference: DexCom, Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | VUSB | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $50.03 |
52-Week Low | $54.84 | $49.60 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
The Vanguard Ultra-Short Bond ETF (VUSB) trades at $49.695, showing minimal daily movement. Technical indicators present a mixed but slightly bullish picture, while the fund is positioned as a cash alternative with a yield of approximately 4.35%. Recent news highlights its appeal amid potential Federal Reserve rate changes and a non-inverted yield curve environment.
The outlook for VUSB is tied to short-term interest rate dynamics, offering an opportunity for investors seeking higher yield than traditional money markets with modestly increased risk. Primary risks include interest rate sensitivity and credit risk within its bond portfolio, which could impact net asset value if market conditions shift.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
